Use of Casirivimab and Imdevimab for the Treatment of COVID-19

The authors present three cases of unvaccinated coronavirus disease 2019 (COVID-19) patients who exhibited symptoms of fever, sore throat, nausea, diarrhea, congestion, and headache. Although they refused COVID-19 vaccination, they presented for the casirivimab and imdevimab monoclonal antibody cock...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ryan, Mangal, Rohan, Stead, Thor S, Barbera, Andrew R, Ganti, Latha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Emergency Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449254/
https://www.ncbi.nlm.nih.gov/pubmed/36106219
http://dx.doi.org/10.7759/cureus.27766
Descripción
Sumario:The authors present three cases of unvaccinated coronavirus disease 2019 (COVID-19) patients who exhibited symptoms of fever, sore throat, nausea, diarrhea, congestion, and headache. Although they refused COVID-19 vaccination, they presented for the casirivimab and imdevimab monoclonal antibody cocktail, which resulted in the resolution of all symptoms. The authors describe the mechanisms and importance of monoclonal antibody treatment for high-risk and unvaccinated patients infected with SARS-CoV-2.

Ejemplares similares